All In Biotech

Drug Trial Radar · NCT03041259

Revascularization of Stenosed Vessels Using Optimized Treatment of Rejuveinix for Reversing Endothelial Dysfunction

A Phase I/IIa Dose-Escalation Study Evaluating the Safety, Tolerability and Efficacy of Rejuveinix in Combination With Standard Interventional Therapy for Critical Limb Ischemia Patients

Last checked: Nov 19, 2026Latest source record: Aug 9, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 320 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

320

Planned (sponsor's estimate)

Start

Jan 2020

Primary completion

Jan 2022

Study completion Jul 2022

Sponsor

Lead sponsor
Reven Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Feb 2, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Single group
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 19 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase I/IIa Dose-Escalation Study Evaluating the Safety, Tolerability and Efficacy of Rejuveinix in Combination With Standard Interventional Therapy for Critical Limb Ischemia Patients with Rutherford Class 4, 5 and 6 Disease

Conditions

  • Critical Limb Ischemia
  • Peripheral Arterial Disease

Interventions

  • Rejuveinix Low DoseDrug

    A intravenous administration of Rejuveinix after standard mechanical intervention of blocked peripheral artery

  • Rejuveinix High DoseDrug

    A intravenous administration of Rejuveinix after standard mechanical intervention of blocked peripheral artery

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Patients with Treatment-related Major Adverse Events as Defined by Re-intervention of the Target Vessel(s), Limb Amputation or Endovascular-related Death.Time frame: 84 days

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.